Royalty Pharma plc

RPRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $618.7M $929.0M $477.0M $1.71B $1.54B $1.01B $246.2M $1.92B
Accounts Receivable
Inventory
Total Current Assets $1.53B $1.80B $1.27B $2.55B $2.88B $2.70B $832.1M
Property, Plant & Equipment
Goodwill $924.6M $0
Intangible Assets (Excl. Goodwill) $0 $5.7M $28.7M $51.7M
Total Assets $19.62B $18.22B $16.38B $16.81B $17.52B $16.02B $12.45B
Liabilities
Accounts Payable
Total Current Liabilities $636.2M $1.25B $161.4M $1.17B $171.3M $307.9M $333.4M
Long-Term Debt $8.57B $6.61B $6.14B $6.12B $7.10B $5.82B $5.96B
Total Liabilities $9.91B $7.88B $6.30B $7.29B $7.27B $6.12B $6.31B
Stockholders' Equity
Retained Earnings $2.36B $2.85B $2.52B $1.96B $2.26B $1.92B $2.83B
Total Stockholders' Equity $9.71B $10.34B $10.08B $9.53B $10.25B $9.90B $6.14B $4.55B
← Newer Page 1 of 2 Older →
Charlie Munger

All I want to know is where I'm going to die so I'll never go there.